{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:58:51Z","timestamp":1789981131977,"version":"4.0.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9,1]]},"DOI":"10.1093\/jac\/dkx190","type":"journal-article","created":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T11:20:19Z","timestamp":1496748019000},"page":"2431-2437","source":"Crossref","is-referenced-by-count":11,"title":["HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors"],"prefix":"10.1093","volume":"72","author":[{"given":"E.","family":"Alessandri-Gradt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Collin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tourneroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bertine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Leoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Charpentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Unal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Descamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"Plantier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,7,6]]},"reference":[{"key":"key\n\t\t\t\t20171012114428_dkx190-B1","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1097\/QAD.0b013e3283355659","article-title":"First evidence of a HIV-1 M\/O recombinant form circulating outside Cameroon","volume":"24","year":"2010","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.meegid.2015.09.006","article-title":"HIV-1 group O infection in Cameroon from 2006 to 2013: prevalence, genetic diversity, evolution and public health challenges","volume":"36","year":"2015","journal-title":"Infect Genet Evol"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B3","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1128\/CMR.00012-13","article-title":"Non-M variants of human immunodeficiency virus type 1","volume":"26","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B4","first-page":"669","article-title":"[Specific diagnosis and follow-up of HIV-1 group O infection: RES-O data]","volume":"40","year":"2010","journal-title":"Med Mal Infect"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B5","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1097\/QAD.0000000000000704","article-title":"Sustained virological failure in Cameroonese patient infected by HIV-1 group N evidenced by sequence-based genotyping assay","volume":"29","year":"2015","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B6","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nm.2016","article-title":"A new human immunodeficiency virus derived from gorillas","volume":"15","year":"2009","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B7","doi-asserted-by":"crossref","first-page":"e1005029.","DOI":"10.1371\/journal.ppat.1005029","article-title":"The two-phase emergence of non pandemic HIV-1 group O in Cameroon","volume":"11","year":"2015","journal-title":"PLoS Pathog"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B8","first-page":"937","article-title":"A placebo-controlled clinical phase I trial with combined anti-HIV-1 and anti-interferon-alpha immunization","volume":"11","year":"1997","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B9","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1097\/00126334-200412150-00001","article-title":"Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups","volume":"37","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/QAI.0b013e318201a904","article-title":"Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M","volume":"56","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B11","doi-asserted-by":"crossref","first-page":"4016.","DOI":"10.1128\/AAC.00100-10","article-title":"Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide","volume":"54","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B12","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1097\/QAD.0b013e3283021c30","article-title":"Integrase polymorphism and HIV-1 group O diversity","volume":"22","year":"2008","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/135965350701200411","article-title":"Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance","volume":"12","year":"2007","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/aid.2012.0196","article-title":"Successful integrase inhibitor-based highly active antiretroviral therapy for a multidrug-class-resistant HIV type 1 group O-infected patient in Cameroon","volume":"29","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B15","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/QAI.0b013e31826327c4","article-title":"Raltegravir-based regimens are effective in HIV-1 group O-infected patients","volume":"61","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B16","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1089\/aid.2015.0318","article-title":"HIV-1 group O genotypes and phenotypes: relationship to fitness and susceptibility to antiretroviral drugs","volume":"32","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/QAI.0000000000000698","article-title":"HIV-1 group O resistance against integrase inhibitors","volume":"70","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B18","doi-asserted-by":"crossref","first-page":"7141","DOI":"10.1128\/AAC.03819-14","article-title":"HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integrase","volume":"58","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B19","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0923-2516(06)80097-X","article-title":"HIV1 sensitivity to zidovudine: need for phenotypic analysis. French Antiretroviral Drug Resistance Working Group","volume":"143","year":"1992","journal-title":"Res Virol"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B20","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/QAI.0b013e3180640cf5","article-title":"Impact of HIV-1 genetic diversity on plasma HIV-1 RNA quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test","volume":"45","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B21","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1128\/JCM.05669-11","article-title":"A new real-time quantitative PCR for diagnosis and monitoring of HIV-1 group O infection","volume":"50","year":"2012","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0166-0934(03)00223-4","article-title":"Plasma viral RNA assay in HIV-1 group O infection by real-time PCR","volume":"113","year":"2003","journal-title":"J Virol Methods"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/01.aids.0000161768.98534.e7","article-title":"HIV-1 resistance genotyping on dried serum spots","volume":"19","year":"2005","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B24","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dkn335","article-title":"HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro","volume":"62","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B25","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1089\/aid.1992.8.1549","article-title":"Signature pattern analysis: a method for assessing viral sequence relatedness","volume":"8","year":"1992","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B26","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.meegid.2016.06.047","article-title":"Differences among HIV-1 subtypes in drug resistance against integrase inhibitors","volume":"46","year":"2016","journal-title":"Infect Genet Evol"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B27","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1097\/QAD.0b013e32833f9e36","article-title":"In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S\/GSK1349572","volume":"24","year":"2010","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B28","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1097\/QAD.0000000000000016","article-title":"In-vitro phenotypic susceptibility of HIV-1 \u2018non-B\u2019 integrase inhibitors naive clinical isolates to dolutegravir and raltegravir","volume":"27","year":"2013","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B29","doi-asserted-by":"crossref","first-page":"E1343","DOI":"10.1073\/pnas.1502022112","article-title":"Origin of the HIV-1 group O epidemic in western lowland gorillas","volume":"112","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20171012114428_dkx190-B30","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1128\/AAC.00397-09","article-title":"Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors","volume":"53","year":"2009","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/72\/9\/2431\/19540462\/dkx190.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T15:58:14Z","timestamp":1719244694000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/72\/9\/2431\/3926538\/HIV1-nongroup-M-phenotypic-susceptibility-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,6]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,7,6]]},"published-print":{"date-parts":[[2017,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx190","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,9]]},"published":{"date-parts":[[2017,7,6]]}}}